Rational design of medium supplementation strategy for improved influenza viruses production based on analyzing nutritional requirements of MDCK Cells
- PMID: 25444832
- DOI: 10.1016/j.vaccine.2014.10.067
Rational design of medium supplementation strategy for improved influenza viruses production based on analyzing nutritional requirements of MDCK Cells
Abstract
Influenza vaccine production using cell culture technology has become popular nowadays. However, to meet the ever increasing demand of influenza vaccine, it is prerequisite to improve the yield of influenza virus in cells. To achieve this, in the present study, the nutritional requirements of MDCK cells in the virus production process were analyzed and a nutrient-feeding strategy was developed accordingly. Based on the consumption rates and corresponding concentration optimization, glucose and fast metabolized amino acids were supplemented into the maintaining medium at the time of infection. Compared with the non-supplemented culture, the average cell specific death rate during 0-48 h post-infection was 0.013 h(-1), which was 40.91% lower in the nutrient-supplemented culture. Total virus titer, HA antigen protein concentration and cell-specific virus yield were (1.88±0.23)×10(3) HA units/50μL, 11.70±0.22 μg/mL and (10.06±1.16)×10(3) virions/cell, respectively, which were 84.04±22.50%, 31.46±2.87% and 86.64±25.81% higher than those in the control, respectively. These data showed that the appropriate supplementation of nutrients during virus production process could reduce cell death, and improve cell-specific virus yield and total influenza virus output. This study laid foundation for the development of cell culture technology for influenza vaccine production.
Keywords: Influenza virus; MDCK cells; Metabolism; Nutritional requirements.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Overcoming nutrient limitations for cell-based production of influenza vaccine.Hum Vaccin Immunother. 2015;11(7):1685-8. doi: 10.1080/21645515.2015.1044182. Hum Vaccin Immunother. 2015. PMID: 26061797 Free PMC article.
-
Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response.Appl Microbiol Biotechnol. 2012 Jan;93(2):601-11. doi: 10.1007/s00253-011-3569-8. Epub 2011 Sep 14. Appl Microbiol Biotechnol. 2012. PMID: 21915610
-
Development and strategies of cell-culture technology for influenza vaccine.Appl Microbiol Biotechnol. 2011 Feb;89(4):893-902. doi: 10.1007/s00253-010-2973-9. Epub 2010 Nov 10. Appl Microbiol Biotechnol. 2011. PMID: 21063703 Review.
-
Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor.Appl Microbiol Biotechnol. 2013 Feb;97(3):1063-70. doi: 10.1007/s00253-012-4375-7. Epub 2012 Sep 4. Appl Microbiol Biotechnol. 2013. PMID: 22945265
-
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).Expert Rev Vaccines. 2009 Jun;8(6):679-88. doi: 10.1586/erv.09.31. Expert Rev Vaccines. 2009. PMID: 19485748 Review.
Cited by
-
Enhanced Production of Herpes Simplex Virus 1 Amplicon Vectors by Gene Modification and Optimization of Packaging Cell Growth Medium.Mol Ther Methods Clin Dev. 2020 Mar 13;17:491-496. doi: 10.1016/j.omtm.2020.03.005. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2020. PMID: 32258212 Free PMC article.
-
Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines.PLoS One. 2015 Nov 5;10(11):e0141686. doi: 10.1371/journal.pone.0141686. eCollection 2015. PLoS One. 2015. PMID: 26540170 Free PMC article.
-
Overcoming nutrient limitations for cell-based production of influenza vaccine.Hum Vaccin Immunother. 2015;11(7):1685-8. doi: 10.1080/21645515.2015.1044182. Hum Vaccin Immunother. 2015. PMID: 26061797 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical